Results 11 to 20 of about 18,455 (220)

Preclinical study of a new 177Lu-labeled somatostatin receptor antagonist in HT-29 human colorectal cancer cells [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2020
Objective(s): Somatostatin receptor-positive neuroendocrine tumors have been targeted using various peptide analogs radiolabeled with therapeutic radionuclides for years.
Hossein Behnammanesh, Mostafa Erfani, Maliheh Hajiramezanali, Safura Jokar, Parham Geramifar, Omid Sabzevari, Mohsen Amini, Mohammad Mazidi, Davood Beiki   +8 more
doaj   +1 more source

Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT

Current Oncology, 2021
Peptide receptor radionuclide therapy (PRRT) is used to treat patients with advanced malignant pheochromocytomas (PCCs) and paragangliomas (PGLs).
Erica S. Tsang, Gayle Funk, Janet Leung, Grace Kalish, Hagen F. Kennecke   +4 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview

Pharmaceuticals, 2021
Primary brain tumors (PBTs) are some of the most difficult types of cancer to treat, and despite advancements in surgery, chemotherapy and radiotherapy, new strategies for the treatment of PBTs are needed, especially for those with poor prognosis such as
Andrea Cimini, Maria Ricci, Francesca Russo, Martina Egidi, Ferdinando Calabria, Antonio Bagnato, Orazio Schillaci, Agostino Chiaravalloti   +7 more
doaj   +1 more source

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor

Case Reports in Oncology, 2020
Tumor-induced osteomalacia is a very rare paraneoplastic syndrome. It can be caused by phosphaturic mesenchymal tumor (PMT), a generally benign tumor that produces fibroblast growth factor 23 (FGF-23), which can cause a severe renal phosphate wasting ...
Simon Häfliger, Ann-Katrin Seidel, Eric Schoch, Jan Reichmann, Damian Wild, Stephanie Steinmann-Schwager, Miklos Pless   +6 more
doaj   +1 more source

PEPTIDE RECEPTOR RADIONUCLIDE THERAPY

Unram Medical Journal, 2021
Peptide receptor radionuclide therapy (PRRT) is an effective and usually well-tolerated treatment for unresectable or metastatic neuroendocrine tumors expressing somatostatin receptors. Somatostatin analog which is labeled by ?- or ?-emitting radionuclide binds specifically to SSTRs abnormally expressed in NETs.
Rian Hidayatullah, Hendra Budiawan, Budi Darmawan, Erwin Affandi   +3 more
openaire   +1 more source

Influence of tumour size on the efficacy of targeted alpha therapy with 213Bi-[DOTA0,Tyr3]-octreotate [PDF]

, 2016
BACKGROUND: Targeted alpha therapy has been postulated to have great potential for the treatment of small clusters of tumour cells as well as small metastases.
Baüm, R.P. (Richard), Blois, E. (Erik) de, Breeman, W.A.P. (Wouter), Bruchertseifer, F. (Frank), Chan, H.S. (Ho Sze), Jong, M. (Marion) de, Koelewijn, S. (Stuart), Konijnenberg, M. (Mark), Morgenstern, A. (Alfred)   +8 more
core   +13 more sources

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours

Cancer Medicine, 2021
Peptide receptor radionuclide therapy (PRRT) is an increasingly used treatment for unresectable neuroendocrine tumours (NETs) that express somatostatin receptors.
Marianne S. Elston, Amanda Love, Dev Kevat, Richard Carroll, Zhen Rong Siow, Sharon Pattison, Veronica Boyle, Eva Segelov, Andrew H. Strickland, David Wyld, Richard Gauci, Kim Kennedy, David Ransom, the Commonwealth Neuroendocrine Tumour Collaboration (CommNETs)   +13 more
doaj   +1 more source

Combination Therapies with PRRT

Pharmaceuticals, 2021
Peptide receptor radionuclide therapy (PRRT) is a successful targeted radionuclide therapy in neuroendocrine tumors (NETs). However, complete responses remain elusive.
Anna Yordanova, Hojjat Ahmadzadehfar
doaj   +1 more source

Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer

Pharmaceutics, 2021
In recent years, radionuclide therapy (RT) and targeted radionuclide therapy (TRT) have gained great interest in cancer treatment. This is due to promising results obtained in both preclinical and clinical studies.
Tyrillshall S. T. Damiana, Simone U. Dalm   +1 more
doaj   +1 more source

PEPTIDE BASED TARGETED RADIONUCLIDE THERAPIES; SCIENCE BEHIND THE SUCCESS.

Journal of Cancer and Allied Specialties, 2016
The radionuclide therapies for solid and liquid malignancies are emerging field nowadays. The targeted radionuclide therapies have been in use since 1945.
Mohammed H Al Rowaily, Daniele Dondi, Marco Chinol, Iqbal Munir, Muaadh AlAsbahi   +4 more
doaj   +1 more source